-
Mashup Score: 0
Participants with an RA risk had various opinions on preventive measures, from being on board, needing to be swayed by a doctor, and fearing the intervention.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0Accelerated Aging Linked to Greater Risk of Rheumatoid Arthritis - 2 month(s) ago
In a new study, cross-sectional analyses showed each 1-year increase in age-adjusted biological age was linked to a 1% – 10% increase in the risk of rheumatoid arthritis.
Source: www.hcplive.comCategories: General Medicine News, General HCPsTweet-
Accelerated aging is linked to a greater increase in #rheumatoid arthritis and could reduce life expectancy, a study found. https://t.co/qbGOLoof8B https://t.co/lehdSVCThF
-
-
Mashup Score: 0
ater and test–retest reliability. Methods: The study included participants with rheumatoid arthritis (RA, n = 18; QST conducted on lower leg) and low back pain (LBP, n = 25; QST conducted on forearm), plus 45 healthy control participants (n = 20 QST on lower leg and n = 25 QST on forearm). Test–retest reliability was assessed from QST conducted 1 to 3 weeks apart. Quantitative sensory testing modalities used were pressure pain detection threshold (PPT) at a site distant to tissue pathology, temporal summation (TS), and conditioned pain modulation (CPM). Temporal summation was calculated as difference or ratio of single and repeated punctate stimuli and unconditioned thresholds for CPM used single or mean of multiple PPTs. Intraclass correlation coefficients (ICCs) were compared between different subgroups. Results: High to very high reliability was found for all assessments of PPT and TS across anatomical sites (lower leg and forearm) and participants (healthy, RA, and LBP) (ICC ≥ 0.77
Source: journals.lww.comCategories: Latest Headlines, RheumatologyTweet-
According to a recent #PAINReports article, quantitative sensory testing is a reliable tool to assess central pain mechanisms in healthy participants and people with #rheumatoid #arthritis and #lowbackpain. https://t.co/3tbRCnGRHp
-
According to a recent #PAINReports article, quantitative sensory testing is a reliable tool to assess central pain mechanisms in healthy participants and people with #rheumatoid #arthritis and #lowbackpain. https://t.co/UIDUDzeVLx
-
-
Mashup Score: 6
Objectives To investigate the efficacy and safety of otilimab, an antigranulocyte-macrophage colony-stimulating factor antibody, in patients with active rheumatoid arthritis. Methods Two phase 3, double-blind randomised controlled trials including patients with inadequate responses to methotrexate (contRAst 1) or conventional synthetic/biologic disease-modifying antirheumatic drugs (cs/bDMARDs; contRAst 2). Patients received background csDMARDs. Through a testing hierarchy, subcutaneous otilimab (90/150 mg once weekly) was compared with placebo for week 12 endpoints (after which, patients receiving placebo switched to active interventions) or oral tofacitinib (5 mg two times per day) for week 24 endpoints. Primary endpoint: proportion of patients achieving an American College of Rheumatology response ≥20% (ACR20) at week 12. Results The intention-to-treat populations comprised 1537 (contRAst 1) and 1625 (contRAst 2) patients. Primary endpoint: proportions of ACR20 responders were stati
Source: ard.bmj.comCategories: Latest Headlines, RheumatologyTweet-
What is new on #rheumatoid #arthritis treatment? ▶️ otilimab (anti-GM-CSF antibody) showed efficacy (ACR20 response) vs placebo in RA with inadequate response to DMARDs ▶️ not as effective as tofacitinib in multiple clinical responses (CDAI and HAQ) 🔗 https://t.co/KFDPTqkZH8 https://t.co/FEQGFQ3DiJ
-
-
Mashup Score: 1Disease-Modifying Antirheumatic Drug Use and Its Effect on... : JCR: Journal of Clinical Rheumatology - 6 month(s) ago
Methods This cohort study included Medicare beneficiaries with diagnosis of RA who received at least 30-day consecutive prescription of opioids in 2017 (n = 23,608). The patients were grouped into non-DMARD and DMARD users, who were further subdivided into regimens set forth by the American College of Rheumatology. The outcome measured was long-term opioid use in 2018 defined as at least 90-day consecutive prescription of opioids. Dose and duration of opioid use were also assessed. A multivariable model identifying factors associated with non-DMARD use was also performed. Results Compared with non-DMARD users, the odds of long-term opioid use were significantly lower among DMARD users (odds ratio, 0.89; 95% confidence interval, 0.83–0.95). All regimens except non–tumor necrosis factor biologic + methotrexate were associated with lower odds of long-term opioid use relative to non-DMARD users. The mean total morphine milligram equivalent, morphine milligram equivalent per day, and total
Source: journals.lww.comCategories: Latest Headlines, RheumatologyTweet-
Effect of Disease-Modifying Anti-Rheumatic Drugs on long-term opioid use in patients with RA. https://t.co/W8BRFkFFoS #Rheumtwitter #Rheumatoid
-
-
Mashup Score: 0Depression and rheumatoid arthritis | NRAS | Mental Wellbeing - 7 month(s) ago
Mental wellbeing is so important and can be prevalent for people with RA. Luckily there are plenty of resources to help you
Source: nras.org.ukCategories: Latest Headlines, RheumatologyTweet-
#Depression in #rheumatoid arthritis is 3⃣x of general population Fatigue & poor sleep could easily be attributed to #arthritis but could also be indicator of poor mood & anxiety Some helpful tips: 👉🏽https://t.co/otfsGA6FyL via @NRAS_UK #WorldMentalHealthDay #mentalhealth https://t.co/lN6SNuSMX3
-
-
Mashup Score: 0Home - 8 month(s) ago
THE VENETIAN LAS VEGAS LAS VEGAS, NEVADA This year we’ re leaving screens completely behind and meeting in person because Perspectives in Rheumatic Diseases (PRD) is more than a conference – we’ re a community. For us, joining together again is an opportunity to enhance the learning experience. As always, our renowned faculty will bring you the latest advancements in rheumatic diseases, from rheumatoid arthritis, lupus, and vasculitis to spondylitis, on top of other urgent issues for practitioners. We
Source: na.eventscloud.comCategories: Dermatology, Latest HeadlinesTweet-
⌛ ONE WEEK LEFT: #PRDlive23. Learn the latest advancements in rheumatic diseases, from #rheumatoid #arthritis, #lupus, and #vasculitis to #spondylitis and much more. Register now: https://t.co/kbaAX80WOD https://t.co/JjGaVZCbxr
-
-
Mashup Score: 14Relationship Between Serum Vitamin D Level and Disease Severity in Rheumatoid Arthritis - 9 month(s) ago
Rheumatoid arthritis is an autoimmune disease that causes joint pain and reduces daily activities. The aim of this study was to evaluate the serum of vitamin D and its relationship with the severity of the disease in patients with rheumatoid arthritis …
Source: PubMed Central (PMC)Categories: Healthcare Professionals, Latest HeadlinesTweet-
RT @HealthyFellow: Relationship Between Serum #Vitamin D Level & Disease Severity in #Rheumatoid #Arthritis https://t.co/fSPs3jjlNx @_at…
-
-
Mashup Score: 0
Background The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different modes of action. Methods Investigator-initiated, randomised, blinded-assessor study. Patients with treatment-naïve early RA with moderate–severe disease activity were…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
🤔 #Certolizumab pegol, #abatacept, or #tocilizumab in early #rheumatoid #arthritis❓ ❗ CDAI remission rates compared to active conventional therapy: ◾ abatacept +20.1%, p<0.001 ◾ certolizumab +13.1%, p=0.021 ◾ tocilizumab +12.7%, p=0.030 https://t.co/jfgEoMyhk4 https://t.co/LTZIRsJjPY
-
-
Mashup Score: 0Home - 10 month(s) ago
This year we’re leaving screens completely behind and meeting in person because Perspectives in Rheumatic Diseases (PRD) is more than a conference–we’re a community. For us, joining together again is an opportunity to enhance the learning experience. As always, our renowned faculty will bring you the latest advancements in rheumatic diseases, from rheumatoid arthritis, lupus, and vasculitis to…
Source: na.eventscloud.comCategories: Dermatology, Latest HeadlinesTweet-
🆕 CONFERENCE ALERT 🚨 DON'T MISS #PRDlive23. Learn the latest advancements in rheumatic diseases, from #rheumatoid #arthritis, #lupus, and #vasculitis to #spondylitis and much more. Register now: https://t.co/B83jqfNDWX https://t.co/9beF63pvQ1
-
People at risk for #rheumatoid arthritis have different views on preventative steps from being eager to take medication or change lifestyle habits to fearing it. Some people stand somewhere in the middle: open to the idea & need advisement from doctors. https://t.co/ZXzr3GB40r